JPWO2021257480A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021257480A5 JPWO2021257480A5 JP2022576871A JP2022576871A JPWO2021257480A5 JP WO2021257480 A5 JPWO2021257480 A5 JP WO2021257480A5 JP 2022576871 A JP2022576871 A JP 2022576871A JP 2022576871 A JP2022576871 A JP 2022576871A JP WO2021257480 A5 JPWO2021257480 A5 JP WO2021257480A5
- Authority
- JP
- Japan
- Prior art keywords
- cfi
- fold
- seq
- amino acid
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003689 Complement Factor I Human genes 0.000 claims 174
- 108090000044 Complement Factor I Proteins 0.000 claims 174
- 125000003275 alpha amino acid group Chemical group 0.000 claims 44
- 230000004048 modification Effects 0.000 claims 33
- 238000012986 modification Methods 0.000 claims 33
- 230000004927 fusion Effects 0.000 claims 25
- 238000006467 substitution reaction Methods 0.000 claims 20
- 238000003776 cleavage reaction Methods 0.000 claims 18
- 230000007017 scission Effects 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 17
- 125000000539 amino acid group Chemical group 0.000 claims 13
- 102000016550 Complement Factor H Human genes 0.000 claims 12
- 108010053085 Complement Factor H Proteins 0.000 claims 12
- 239000000758 substrate Substances 0.000 claims 12
- 102220482065 Nuclear cap-binding protein subunit 2_Y20F_mutation Human genes 0.000 claims 11
- 102220477915 Protein phosphatase 1 regulatory subunit 12C_E38A_mutation Human genes 0.000 claims 11
- 238000004519 manufacturing process Methods 0.000 claims 10
- 239000004606 Fillers/Extenders Substances 0.000 claims 9
- 102000004961 Furin Human genes 0.000 claims 8
- 108090001126 Furin Proteins 0.000 claims 8
- 230000004075 alteration Effects 0.000 claims 8
- 230000004154 complement system Effects 0.000 claims 8
- 208000035404 Autolysis Diseases 0.000 claims 7
- 206010057248 Cell death Diseases 0.000 claims 7
- 101710136015 Low-density lipoprotein receptor 1 Proteins 0.000 claims 7
- 101710136018 Low-density lipoprotein receptor 2 Proteins 0.000 claims 7
- 102220537509 Partner and localizer of BRCA2_K14A_mutation Human genes 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 230000028043 self proteolysis Effects 0.000 claims 7
- 102000009027 Albumins Human genes 0.000 claims 6
- 108010088751 Albumins Proteins 0.000 claims 6
- 108010078015 Complement C3b Proteins 0.000 claims 6
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 101710184994 Complement control protein Proteins 0.000 claims 5
- 102000000185 SRCR domains Human genes 0.000 claims 5
- 108050008568 SRCR domains Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 4
- 101000737565 Homo sapiens Complement factor I Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229920002988 biodegradable polymer Polymers 0.000 claims 4
- 239000004621 biodegradable polymer Substances 0.000 claims 4
- 108010052926 complement C3d,g Proteins 0.000 claims 4
- 102000057666 human CFI Human genes 0.000 claims 4
- 238000003780 insertion Methods 0.000 claims 4
- 230000037431 insertion Effects 0.000 claims 4
- 239000000395 magnesium oxide Substances 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 230000017854 proteolysis Effects 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 102100025721 Cytosolic carboxypeptidase 2 Human genes 0.000 claims 3
- 102100025707 Cytosolic carboxypeptidase 3 Human genes 0.000 claims 3
- 101000932634 Homo sapiens Cytosolic carboxypeptidase 2 Proteins 0.000 claims 3
- 101000932588 Homo sapiens Cytosolic carboxypeptidase 3 Proteins 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims 3
- 101001033011 Mus musculus Granzyme C Proteins 0.000 claims 3
- 101001033009 Mus musculus Granzyme E Proteins 0.000 claims 3
- 230000004988 N-glycosylation Effects 0.000 claims 3
- 102000004142 Trypsin Human genes 0.000 claims 3
- 108090000631 Trypsin Proteins 0.000 claims 3
- 230000003321 amplification Effects 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 230000007062 hydrolysis Effects 0.000 claims 3
- 238000006460 hydrolysis reaction Methods 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims 3
- 239000012588 trypsin Substances 0.000 claims 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 2
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 2
- 208000033564 Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome Diseases 0.000 claims 2
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 206010018910 Haemolysis Diseases 0.000 claims 2
- 206010019860 Hereditary angioedema Diseases 0.000 claims 2
- 101000932590 Homo sapiens Cytosolic carboxypeptidase 4 Proteins 0.000 claims 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 2
- 102220497574 Leukotriene B4 receptor 1_N52Q_mutation Human genes 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 101001033003 Mus musculus Granzyme F Proteins 0.000 claims 2
- -1 N531 Substances 0.000 claims 2
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 102220543174 Protein adenylyltransferase FICD_N446Q_mutation Human genes 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 102220538874 SUMO-conjugating enzyme UBC9_N85Q_mutation Human genes 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 2
- 102220603331 Zona pellucida sperm-binding protein 3_N159Q_mutation Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 108010047295 complement receptors Proteins 0.000 claims 2
- 102000006834 complement receptors Human genes 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 230000008482 dysregulation Effects 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 230000008588 hemolysis Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 239000000231 karaya gum Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 2
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000008795 neuromyelitis optica Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000000276 potassium ferrocyanide Substances 0.000 claims 2
- 230000009467 reduction Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000029574 C3 glomerulopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 101710155594 Coiled-coil domain-containing protein 115 Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 1
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102100035027 Cytosolic carboxypeptidase 1 Human genes 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 claims 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims 1
- 102220480123 H/ACA ribonucleoprotein complex subunit DKC1_R35A_mutation Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
- 206010027202 Meningitis bacterial Diseases 0.000 claims 1
- 206010063916 Metastatic gastric cancer Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 101100113065 Mus musculus Cfi gene Proteins 0.000 claims 1
- 206010028424 Myasthenic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 102220482064 Nuclear cap-binding protein subunit 2_Y20A_mutation Human genes 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102220617947 Putative uncharacterized protein LOC152225_F29A_mutation Human genes 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000013128 Squamous cell carcinoma of pancreas Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000033809 Suppuration Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036866 Vitreoretinopathy Diseases 0.000 claims 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000009904 bacterial meningitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 208000027134 non-immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000006691 pancreatic squamous cell carcinoma Diseases 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 201000010434 protein-losing enteropathy Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 102200037713 rs34068461 Human genes 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000000106 sweat gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038874P | 2020-06-14 | 2020-06-14 | |
| US63/038,874 | 2020-06-14 | ||
| US202063122437P | 2020-12-07 | 2020-12-07 | |
| US63/122,437 | 2020-12-07 | ||
| US202063124698P | 2020-12-11 | 2020-12-11 | |
| US63/124,698 | 2020-12-11 | ||
| US202163179160P | 2021-04-23 | 2021-04-23 | |
| US63/179,160 | 2021-04-23 | ||
| PCT/US2021/037278 WO2021257480A2 (en) | 2020-06-14 | 2021-06-14 | Complement factor i-related compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529497A JP2023529497A (ja) | 2023-07-10 |
| JPWO2021257480A5 true JPWO2021257480A5 (enrdf_load_stackoverflow) | 2024-06-17 |
Family
ID=76859730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576871A Pending JP2023529497A (ja) | 2020-06-14 | 2021-06-14 | 補体因子ｉ関連組成物および方法 |
Country Status (8)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021257480A2 (en) | 2020-06-14 | 2021-12-23 | Catalyst Biosciences, Inc. | Complement factor i-related compositions and methods |
| GB202018320D0 (en) * | 2020-11-20 | 2021-01-06 | Univ Newcastle | Methods of producing recombinant complement proteins |
| EP4141026A1 (en) * | 2021-08-31 | 2023-03-01 | Aarhus Universitet | Fusion proteins comprising anti c3b single domain antibody for complement regulation |
| TW202323270A (zh) | 2021-11-04 | 2023-06-16 | 英商自由行療法有限公司 | 多肽 |
| IL313777A (en) * | 2021-12-22 | 2024-08-01 | Vertex Pharma | Complement factor-i formulations |
| TW202400627A (zh) * | 2022-05-04 | 2024-01-01 | 美商維泰克斯製藥公司 | 用於治療眼部疾病之補體因子i之給藥方案 |
| WO2024118575A2 (en) * | 2022-11-28 | 2024-06-06 | Adverum Biotechnologies, Inc. | Aav variants for the treatment of dry amd |
| WO2024223935A1 (en) * | 2023-04-28 | 2024-10-31 | eleva GmbH | Sialylated human factor h protein and therapeutic use thereof |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0742235B2 (ja) | 1985-11-08 | 1995-05-10 | 三共株式会社 | 自己免疫性疾病の予防・治療剤 |
| EP0649468B1 (en) | 1992-06-24 | 2000-03-15 | AdProTech plc | Soluble cr1 derivatives |
| DE4222534A1 (de) | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
| WO1999044625A1 (en) | 1998-03-03 | 1999-09-10 | John Hopkins University | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| EP2067488A1 (en) | 2000-04-12 | 2009-06-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2004506408A (ja) | 2000-04-26 | 2004-03-04 | イルーシス セラポーティクス，インコーポレーテッド | 二重特異性分子及びその用途 |
| DE60232101D1 (enrdf_load_stackoverflow) | 2001-12-28 | 2009-06-04 | Kyowa Hakko Kogyo Kk | |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| NZ608860A (en) | 2005-02-14 | 2014-10-31 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| DK2256135T3 (da) | 2006-06-14 | 2019-06-11 | Csl Behring Gmbh | Proteolytisk spaltbart fusionsprotein, der omfatter en blodkoagulationsfaktor |
| EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| PL2044111T3 (pl) | 2006-06-21 | 2015-02-27 | Musc Found For Res Dev | Celowanie czynnika H dopełniacza do leczenia chorób |
| GB0904427D0 (en) | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| RU2607374C2 (ru) * | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
| GB0922659D0 (en) | 2009-12-24 | 2010-02-10 | Univ Edinburgh | Factor H |
| AU2011222883B2 (en) | 2010-03-05 | 2016-05-26 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
| AU2011270959A1 (en) | 2010-06-22 | 2013-01-10 | Musc Foundation For Research Development | Antibodies to the C3d fragment of complement component 3 |
| WO2012037370A1 (en) | 2010-09-15 | 2012-03-22 | Celldex Therapeutics, Inc. | Treatment of chronic nephropathies using soluble complement receptor type i (scr1) |
| KR20180072851A (ko) | 2011-04-08 | 2018-06-29 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| JP2016502850A (ja) * | 2012-12-18 | 2016-02-01 | ノバルティス アーゲー | ヒアルロナンに結合するペプチドタグを使用する組成物及び方法 |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| US10183988B2 (en) | 2013-06-07 | 2019-01-22 | Duke University | Anti-Complement factor H antibodies |
| EP3033093A1 (en) | 2013-08-16 | 2016-06-22 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| CN104231085B (zh) | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
| GB201318170D0 (en) | 2013-10-14 | 2013-11-27 | Univ Edinburgh | Proteins with Diagnostic and Therapeutic Uses |
| JP6702866B2 (ja) | 2013-11-18 | 2020-06-03 | ルビウス セラピューティクス， インコーポレイテッド | 合成膜−レシーバー複合体 |
| WO2015105973A1 (en) | 2014-01-08 | 2015-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| WO2015153102A1 (en) | 2014-04-01 | 2015-10-08 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
| EP3151845A4 (en) | 2014-06-05 | 2018-01-17 | The Regents of the University of Colorado, a body corporate | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
| RU2727411C2 (ru) | 2015-09-24 | 2020-07-21 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиция и способ для лечения заболевания, опосредованного комплементом |
| US11903996B2 (en) | 2015-10-07 | 2024-02-20 | David C. Fritzinger | Modulators of complement function |
| US10975131B2 (en) | 2015-10-27 | 2021-04-13 | University Of Massachusetts | Factor H-Fc immunotheraphy |
| GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| CN106928371B (zh) | 2015-12-31 | 2021-06-08 | 江苏匡亚生物医药科技有限公司 | 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用 |
| GB201608046D0 (en) | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| PL3474883T3 (pl) | 2016-06-28 | 2022-09-19 | Universität Ulm | Inhibitory dopełniacza i ich zastosowania |
| WO2018075474A1 (en) | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating central nervous system injury |
| US11912750B2 (en) * | 2016-11-10 | 2024-02-27 | Keros Therapeutics, Inc. | GDNF fusion polypeptides and methods of use thereof |
| MX2019005687A (es) * | 2016-11-22 | 2019-09-05 | Klotho Therapeutics Inc | Proteinas klotho recombinantes novedosas y composiciones y metodos que involucran a las mismas. |
| EP4129321A1 (en) * | 2016-12-05 | 2023-02-08 | Nuritas Limited | Compositions comprising peptide wkdeagkplvk |
| GB201704071D0 (en) * | 2017-03-14 | 2017-04-26 | Univ Newcastle | Recombinant mature complement factor 1 |
| GB201706808D0 (en) | 2017-04-28 | 2017-06-14 | Univ Newcastle | Modified complement proteins and uses thereof |
| GB201709222D0 (en) | 2017-06-09 | 2017-07-26 | Univ Manchester | C3b Inactivating Polypeptide |
| JP2021500922A (ja) | 2017-10-20 | 2021-01-14 | ジェミニ・セラピューティクス・インコーポレイテッドＧｅｍｉｎｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 加齢黄斑変性を処置するための組成物および方法 |
| CA3100071A1 (en) | 2018-05-16 | 2019-11-21 | Csl Limited | Soluble complement receptor type 1 variants and uses thereof |
| US20210371480A1 (en) * | 2018-10-23 | 2021-12-02 | Gemini Therapeutics Inc. | Compositions and methods for treating age-related macular degeneration and other diseases |
| US20200325481A1 (en) | 2018-11-16 | 2020-10-15 | Gemini Therapeutics Inc. | Antisense-based therapeutics for targeting htra1 and methods of use |
| WO2020102680A1 (en) | 2018-11-16 | 2020-05-22 | Gemini Therapeutics Inc. | Antibody-based therapeutics for targeting htra1 and methods of use |
| US20200291427A1 (en) | 2018-11-16 | 2020-09-17 | Gemini Therapeutics Inc. | Crispr-based therapeutics for targeting htra1 and methods of use |
| US20200270614A1 (en) | 2018-11-16 | 2020-08-27 | Gemini Therapeutics Inc. | RNAi-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| EP3893916A4 (en) | 2018-12-11 | 2023-03-29 | Q32 Bio Inc. | FUSION PROTEIN CONSTRUCTS FOR A COMPLEMENT-ASSOCIATED DISEASE |
| GB201821089D0 (en) | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Codon-optimised complement factor I |
| GB201821082D0 (en) | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
| EP3999073A4 (en) | 2019-07-17 | 2023-07-26 | Gemini Therapeutics Sub, Inc. | Factor h potentiating antibodies and uses thereof |
| US20220395557A1 (en) | 2019-10-23 | 2022-12-15 | Gemini Therapeutics Sub, Inc. | Methods for treating patients having cfh mutations with recombinant cfh proteins |
| EP4048319A1 (en) | 2019-10-23 | 2022-08-31 | Gemini Therapeutics Sub, Inc. | Methods for treating patients having cfh mutations with cfh-encoding vectors |
| US20220347265A1 (en) | 2019-10-23 | 2022-11-03 | Gemini Therapeutics Sub, Inc. | Methods for treating patients having cfi mutations with recombinant cfi proteins |
| WO2021257480A2 (en) | 2020-06-14 | 2021-12-23 | Catalyst Biosciences, Inc. | Complement factor i-related compositions and methods |
| GB202009741D0 (en) | 2020-06-25 | 2020-08-12 | Freeline Therapeutics Ltd | Polynucleotide |
| GB202010009D0 (en) | 2020-06-30 | 2020-08-12 | Syncona Investment Man Ltd | Vector |
| GB202107754D0 (en) | 2021-05-31 | 2021-07-14 | Univ Newcastle | Screening for the effects of complement protein changes |
| TW202323270A (zh) | 2021-11-04 | 2023-06-16 | 英商自由行療法有限公司 | 多肽 |
-
2021
- 2021-06-14 WO PCT/US2021/037278 patent/WO2021257480A2/en active Application Filing
- 2021-06-14 CA CA3182800A patent/CA3182800A1/en active Pending
- 2021-06-14 EP EP21740305.4A patent/EP4165181A2/en active Pending
- 2021-06-14 AU AU2021293174A patent/AU2021293174A1/en active Pending
- 2021-06-14 US US17/347,442 patent/US12116606B2/en active Active
- 2021-06-14 JP JP2022576871A patent/JP2023529497A/ja active Pending
- 2021-06-14 IL IL299048A patent/IL299048A/en unknown
- 2021-06-15 TW TW110121746A patent/TW202212350A/zh unknown
-
2024
- 2024-09-09 US US18/829,234 patent/US20250136965A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU699748B2 (en) | Recombinant HK2 polypeptide | |
| US7087411B2 (en) | Fusion protein capable of binding VEGF | |
| US12116606B2 (en) | Complement factor I-related compositions and methods | |
| JPH10500298A (ja) | 三量体化ポリペプチド、その製造及び使用 | |
| WO1995030758A9 (en) | Recombinant hk2 polypeptide | |
| WO1994011401A1 (en) | Human homolog of the e-cadherin gene and methods based thereon | |
| JPWO2021257480A5 (enrdf_load_stackoverflow) | ||
| US20080234191A1 (en) | Human complement C3 derivates with cobra venom factor-like function | |
| CN100586960C (zh) | HAb18GC2单抗和其轻、重链可变区基因及应用 | |
| US5763182A (en) | RPDL protein and DNA encoding the same | |
| US20130336972A1 (en) | Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc | |
| CN118804759A (zh) | 补体因子i相关的组合物和方法 | |
| US7011967B1 (en) | Seripancrin | |
| TWI881372B (zh) | Ｎ-末端和/或ｃ-末端切割的可溶性ｐｈ２０多肽及其用途 | |
| JP2001509391A (ja) | ウシｉｆ１ａｔｐアーゼインヒビタータンパク質由来のコイルドコイル構造を含む融合タンパク質 | |
| US5567602A (en) | Recombinant production of chymase | |
| JP5757555B2 (ja) | 新規酸性プロテアーゼ及びその用途 | |
| TWI896460B (zh) | N-末端和/或c-末端切割的可溶性ph20多肽及其用途 | |
| JP4564791B2 (ja) | スタテリン融合タンパク質 | |
| JPH04210700A (ja) | 組換ヒトトロンボモジュリン誘導体 | |
| US20030064431A1 (en) | Complement receptor type 1 (cr1)-like sequences | |
| JP2901291B2 (ja) | 新規ポリペプチド及びその遺伝子 | |
| JPH0728746B2 (ja) | 新規プラスミド、微生物細胞及びヒト免疫グロブリンＧ Ｆｃ領域蛋白質の製造法 | |
| JP3398427B2 (ja) | 成長ホルモンの生産方法 | |
| JP3669062B2 (ja) | 新規蛋白質およびそれをコードするｄｎａ並びに該蛋白質の産生方法 |